50th patient recruited for CARE CF 1 Lynovex clinical study

NovaBiotics today announces that the 50th patient has been recruited for the CARE-CF-1 clinical study (NBTCS-02) investigating Lynovex® as a novel intervention in Cystic Fibrosis (CF) infectious exacerbations. The trial aims to assess the benefits of oral Lynovex® as an adjunct (“add on”) therapy to standard of care interventions in CF infectious exacerbations. The target total patient number for inclusion in CARE-CF 1 is 120 adult patients in Europe and the US so randomising 50 subjects into the trial is a significant milestone. For further details of the study please see [ https://clinicaltrials.gov/sho... ] here.